TELA · Tela Bio, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $80.28M | $69.30M | $58.45M | $41.42M | $29.46M | $18.21M |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | $54.34M | $46.49M | $40.11M | $27.04M | $18.81M | $11.23M |
| R&D | $9.22M | $8.81M | $9.62M | $8.94M | $6.74M | $4.25M |
| SG&A | $15.69M | $14.72M | $14.89M | $13.86M | $12.46M | $10.14M |
| Total Operating Expenses | $88.10M | $88.18M | $84.19M | $66.05M | $48.26M | $36.51M |
| D&A | $630.0K | $632.0K | $428.0K | $383.0K | $231.0K | $221.0K |
| Operating Income | ($33.76M) | ($34.12M) | ($44.08M) | ($39.01M) | ($29.45M) | ($25.27M) |
| Interest Expense | $5.25M | $5.29M | $5.22M | $4.05M | $3.60M | $3.56M |
| Income Tax | $230.0K | ($144.0K) | - | - | - | - |
| Net Income | ($38.83M) | ($37.84M) | ($46.66M) | ($44.30M) | ($33.28M) | ($28.79M) |
| EPS - Basic | ($0.83) | ($1.33) | ($2.04) | ($2.72) | ($2.23) | - |
| EPS - Diluted | ($0.83) | ($1.33) | ($2.04) | ($2.72) | ($2.23) | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $50.84M | $52.67M | $46.73M | $42.02M | $43.93M | $74.39M |
| Accounts Receivable | $10.35M | $10.10M | $9.74M | $6.62M | $4.23M | $2.68M |
| Inventory | $11.02M | $12.78M | $13.16M | $11.79M | $7.66M | $3.91M |
| Accounts Payable | $2.31M | $2.15M | $1.67M | $1.53M | $2.41M | $652.0K |
| Current Assets | $75.58M | $78.07M | $71.73M | $62.45M | $59.05M | $83.22M |
| Total Assets | $81.42M | $86.57M | $78.05M | $67.86M | $62.54M | $86.46M |
| Current Liabilities | $17.98M | $15.60M | $16.97M | $12.40M | $10.57M | $6.61M |
| Long-term Debt | $55.65M | $41.12M | $40.52M | $39.92M | $31.49M | $30.83M |
| Total Liabilities | $75.11M | $58.11M | $59.17M | $53.55M | $42.45M | $37.43M |
| Stockholders' Equity | $6.31M | $28.46M | $18.88M | $14.30M | $20.10M | $49.03M |
| Retained Earnings | ($397.56M) | ($358.73M) | ($320.89M) | ($274.23M) | ($229.93M) | ($196.65M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($28.22M) | ($41.59M) | ($40.86M) | ($40.75M) | ($30.43M) | ($24.46M) |
| Investing Cash Flow | $846.0K | $4.45M | ($599.0K) | ($1.87M) | ($627.0K) | $9.12M |
| Financing Cash Flow | $25.75M | $43.06M | $46.27M | $40.85M | $585.0K | $44.41M |
| CapEx | $448.0K | $989.0K | $611.0K | $872.0K | $627.0K | $167.0K |
| Free Cash Flow | ($28.67M) | ($42.58M) | ($41.47M) | ($41.62M) | ($31.06M) | ($24.62M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 67.7% | 67.1% | 68.6% | 65.3% | 63.9% | 61.7% |
| Operating margin | -42.0% | -49.2% | -75.4% | -94.2% | -100.0% | -138.8% |
| EBITDA margin | -41.3% | -48.3% | -74.7% | -93.3% | -99.2% | -137.6% |
| Net margin | -48.4% | -54.6% | -79.8% | -106.9% | -112.9% | -158.1% |
| Free cash flow margin | -35.7% | -61.4% | -70.9% | -100.5% | -105.4% | -135.2% |
| FCF / Net income | 0.74 | 1.13 | 0.89 | 0.94 | 0.93 | 0.86 |
| R&D / Revenue | 11.5% | 12.7% | 16.5% | 21.6% | 22.9% | 23.4% |
| SG&A / Revenue | 19.6% | 21.2% | 25.5% | 33.5% | 42.3% | 55.7% |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -47.7% | -43.7% | -59.8% | -65.3% | -53.2% | -33.3% |
| Return on equity | -615.1% | -133.0% | -247.1% | -309.7% | -165.6% | -58.7% |
| Return on invested capital | -43.0% | -38.7% | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 4.20 | 5.01 | 4.23 | 5.03 | 5.58 | 12.60 |
| Quick ratio | 3.59 | 4.19 | 3.45 | 4.08 | 4.86 | 12.01 |
| Cash ratio | 2.83 | 3.38 | 2.75 | 3.39 | 4.15 | 11.26 |
| Leverage | ||||||
| Debt / Equity | 8.82 | 1.45 | 2.15 | 2.79 | 1.57 | 0.63 |
| Debt / Assets | 0.68 | 0.48 | 0.52 | 0.59 | 0.50 | 0.36 |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | -6.4x | -6.4x | -8.4x | -9.6x | -8.2x | -7.1x |
| Equity multiplier | 12.90 | 3.04 | 4.13 | 4.74 | 3.11 | 1.76 |
| Liabilities / Assets | 0.92 | 0.67 | 0.76 | 0.79 | 0.68 | 0.43 |
| Efficiency | ||||||
| Asset turnover | 0.99 | 0.80 | 0.75 | 0.61 | 0.47 | 0.21 |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | 47d | 53d | 61d | 58d | 52d | 54d |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | 8.8x | 3.0x | 8.0x | 13.1x | 8.2x | - |
| P / S | 0.7x | 1.2x | 2.6x | 4.5x | 5.6x | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | 15.8% | 18.6% | 41.1% | 40.6% | 61.8% | 329.0% |
| Revenue CAGR (3y) | 24.7% | 33.0% | 47.5% | 113.7% | - | - |
| Revenue CAGR (5y) | 34.5% | 74.8% | - | - | - | - |
| Gross profit growth (YoY) | 16.9% | 15.9% | 48.3% | 43.8% | 67.5% | 343.7% |
| Operating income growth (YoY) | 1.1% | 22.6% | -13.0% | -32.4% | -16.5% | -49.3% |
| Net income growth (YoY) | -2.6% | 18.9% | -5.3% | -33.1% | -15.6% | -35.0% |
| EPS growth (YoY) | 37.6% | 34.8% | 25.0% | -22.0% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | 32.7% | -2.7% | 0.4% | -34.0% | -26.1% | -48.6% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -77.8% | 50.7% | 32.0% | -28.8% | -59.0% | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$80.28M totalSingle Reportable Segment$80.28M · 100.0%
Geographic
$12.10M totalNon Us$12.10M · 100.0%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
-3.90
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
3/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- ✗Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- ✓Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing TELA Bio against the 5 most active filers in the same SIC group.